ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

NCCN Updates Breast Cancer Guidelines for Patients

October 31, 2003

BMS, ImClone To Develop New Drug IMC-C225, Targets EGF Receptor.

September 28, 2001

In Brief: Rogers Indicates He May Let Training Grant Bill Die

March 29, 1974

Garb’s Questions, Answers About Cancer Program

December 12, 1980

BMS Demands Resignation Of Two ImClone Executives

February 8, 2002

NIH Construction: Clinton, NIH Officials Dedicate Vaccine Research Center

June 11, 1999